1856 completed, 560 unknown, 328 recruiting, 241 terminated. 762 Not applicable, 452 Phase 3, 330 Phase 4, 320 Phase 2, 159 Phase 1.
Follow Embolism and Thrombosis: new trials by email Literature Review of Embolism and Thrombosis trials Research Report on Embolism and Thrombosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety And Field Evaluation of Plasma Lyophilized for Acute and Surgical Management Applications Freeze-Dried Plasma, Conventional Plasma - Thromboembolic Event, FDP | Phase 4 | Not yet recruiting | Teleflex | 867 | 2027-10-01 | 2026-09-30 |
| A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC) - Venous Thromboembolism, Children Under 2 Years | Not yet recruiting | Bayer | 850 | 2027-09-01 | 2026-10-02 | |
| Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP). Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Not yet recruiting | Johns Hopkins All Children's Hospital | 802 | 2027-04-15 | 2026-05-26 |
| SAFELY RULING OUT DEEP VEIN THROMBOSIS IN PREGNANCY WITH THE LEFt SCORE AND TRIMESTER-ADJUSTED D-DIMER CUTOFFS (the PREG-DVT Study): A PROSPECTIVE COHORT STUDY. D-dimer - Pregnancy Related, Deep Vein Thrombosis | Not applicable | Not yet recruiting | Marc Righini | 330 | 2027-04-01 | 2026-10-21 |
| Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients Quantra System - Pediatric, Coagulation | Not yet recruiting | HemoSonics LLC | 240 | 2027-03-15 | 2026-09-17 | |
| Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator - Pulmonary Embolism, Right Ventricular Dysfunction | Suspended | Brigham and Women's Hospital | 60 | 2027-01-01 | 2026-01-21 | |
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome Vitamin K Antagonist - Drug, Anticoagulant Therapy Discontinuation - Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 234 | 2026-12-01 | 2026-10-15 |
| Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occlusion: The RE-DRT Study Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT) | Not yet recruiting | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | 100 | 2026-12-01 | 2026-03-24 | |
| LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus Continue rivaroxaban or apixaban or warfarin, Discontinue rivaroxaban or apixaban or warfarin - Left Ventricular Thrombus | Phase 2 | Not yet recruiting | Queen Mary University of London | 120 | 2026-12-01 | 2026-02-27 |
| Investigating a Personalized Approach to Anti-Platelet Therapy Genotyping guided therapy for anti-platelet management - High Risk Bleeding | Phase 4 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 1760 | 2026-12-01 | 2026-11-03 |
| TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study Experimental group: ticagrelor, Control group: placebo - Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 274 | 2026-11-24 | 2026-11-06 |
| Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study Delayed Un-gated CT Scan for Left Atrial Appendage Thrombus, Delayed Gated CT Scan for Left Atrial Appendage Thrombus - Atrial Fibrillation (AF), Pulmonary Embolism (PE) | Not applicable | Not yet recruiting | Northwell Health | 60 | 2026-11-01 | 2026-10-26 |
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF) blood sampling for measuring anti-Xa activity, measurement of anti-XA activity - Congenital Heart Disease, Unfractionated Heparin | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de la Réunion | 22 | 2026-11-01 | 2026-09-21 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features Alteplase, Standard Anticoagulation - Pulmonary Embolism | Phase 3 | Not yet recruiting | China National Center for Cardiovascular Diseases | 270 | 2026-11-01 | 2026-11-04 |
| Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism Thrombolysis Catheter - Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement | Not applicable | Not yet recruiting | Flow Medical Solutions, Inc. | 20 | 2026-11-01 | 2026-11-06 |
| Regulation of Platelet Function in Older Patients With Atrial Fibrillation Atrial Fibrillation, Thrombotic Risk | Not yet recruiting | University of Michigan | 50 | 2026-11-01 | 2026-11-09 | |
| Viscoelastic Coagulation Monitoring for Early Identification of Sepsis: The VISION II Study Viscoelastic Coagulation Monitor (VCM) testing - Sepsis, Infection | Not yet recruiting | Hellenic Institute for the Study of Sepsis | 400 | 2026-11-01 | 2026-11-10 |
Showing 20 of 3285. Sign in to see all of them.
Thrombosis (955) · Pulmonary Embolism (783) · Venous Thrombosis (763) · Venous Thromboembolism (698) · Thromboembolism (288) · Retinal Vein Occlusion (276) · Hemorrhage (178) · Atrial Fibrillation (163) · Stroke (154) · Macular Edema (113) · Neoplasms (110) · Cardiovascular Diseases (102) · Embolism (94) · COVID-19 (92) · Raynaud Disease (80)
Vascular Diseases (3255) · Cardiovascular Diseases (3183) · Thrombosis (1123) · Respiratory Tract Diseases (904) · Lung Diseases (875) · Pathological Conditions, Signs and Symptoms (861) · Embolism (785) · Pathologic Processes (767) · Thromboembolism (739) · Heart Diseases (395) · Nervous System Diseases (377) · Venous Thrombosis (342) · Central Nervous System Diseases (304) · Brain Diseases (294)
Rivaroxaban (191) · Enoxaparin (175) · Warfarin (114) · apixaban (113) · Aspirin (86) · Heparin (69) · Heparin, Low-Molecular-Weight (62) · Ranibizumab (60) · Dalteparin (59) · Blood Specimen Collection (55) · Dabigatran (55) · Fondaparinux (42) · Clopidogrel (40) · Tissue Plasminogen Activator (40) · edoxaban (38)
Bayer (77) · Assistance Publique - Hôpitaux de Paris (44) · Brigham and Women's Hospital (39) · Bristol-Myers Squibb (39) · University Hospital, Brest (38) · Ottawa Hospital Research Institute (32) · Assiut University (31) · Boehringer Ingelheim (29) · Sanofi (28) · McMaster University (27) · National Heart, Lung, and Blood Institute (NHLBI) (23) · GlaxoSmithKline (21) · Novartis Pharmaceuticals (21) · HemoSonics LLC (19) · Insel Gruppe AG, University Hospital Bern (19)
United States (944) · France (459) · Canada (316) · China (279) · Italy (248) · Germany (239) · United Kingdom (209) · Spain (197) · Netherlands (170) · Denmark (152) · Switzerland (138) · Belgium (135) · Austria (130) · Sweden (129) · Poland (126)
Shirley Wang, PhD, ScM (7) · Samuel Z Goldhaber, MD (6) · Samuel Z. Goldhaber, MD (6) · Gregory Piazza, MD, MS (5)
PMID 33779986, PMID 33337539, PMID 35244208, PMID 39968829, PMID 33502773, PMID 38189593, PMID 35570249, PMID 36912792, PMID 37591523, PMID 40163217, PMID 24081972, PMID 28762617, PMID 33086312, PMID 34622445, PMID 36413425, PMID 37929840, PMID 22371186, PMID 22429800, PMID 22709460, PMID 22863355, PMID 23425163, PMID 23629822, PMID 25698905, PMID 27807306, PMID 28617144, PMID 29976287, PMID 31420317, PMID 32633861, PMID 32657973, PMID 34127618, PMID 34172290, PMID 34597414, PMID 34878173, PMID 38941511, PMID 15319720, PMID 15842354, PMID 17855670, PMID 18190818, PMID 19017588, PMID 19348685, PMID 19920268, PMID 20696966, PMID 20860504, PMID 21128814, PMID 22172244, PMID 22315264, PMID 22429908, PMID 22449293, PMID 22995531, PMID 23013426
2014 (11), 2018 (11), 2009 (10), 2015 (10), 2016 (10), 2019 (9), 2023 (9), 2025 (8), 2017 (7), 2005 (6), 2008 (6), 2004 (3), K23HL132054 (2), R01HL114405 (2), 1UG1EY026876-01A1 (1)